Suzhou Connect Biopharmaceuticals, Ltd.

10th Floor, XiangTang Development Building
#3 ChaoYang Dong Road
Jiangsu Province

Tel: 0512-53577866


Show jobs for this employer

About Suzhou Connect Biopharmaceuticals, Ltd.

Suzhou Connect Biopharma is a clinical-stage company that discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. We identify and advance our drug candidates through in-house discovery and in-licensing, while leveraging qualified CROs for further development. We successfully completed a phase I clinical trial study on our leading program CBP-307, a novel and selective second generation S1P1 (a G-protein coupled receptor -GPCR) modulator for the treatment of a range of autoimmune disorders, including multiple sclerosis, inflammatory bowel disease and psoriasis. The randomized, double-blind, placebo controlled study assessed the tolerability, pharmacokinetics and pharmacodynamics of CBP-307 in Melbourne Australia, and CBP-307 exhibited excellent safety features and potent T cell modulation activity as well as optimal pharmacokinetics and pharmacodynamics profiles, demonstrating the best-in-class potential. Meanwhile, we are advancing other preclinical programs including CBP-174 and CBP-201. CBP-174 is a small molecule inhibitor of a GPCR involved in allergic rhinitis and atopic dermatitis. This is an in-licensed program in which we hold exclusive global development and commercialization rights. CBP-201 is an internally-discovered monoclonal antibody for the treatment of asthma, atopic dermatitis and other diseases.
Founders: Zheng Wei and William (Wubin) Pan
Founder and CEO: Zheng Wei
Please click here for Connect Biopharma job opportunities.
Please click here for clinical trial information.

24 articles about Suzhou Connect Biopharmaceuticals, Ltd.